RxDoctor Payments DataLook up a doctor →

Michael Istfan, MD

Rheumatology · South Charleston, WVNPI 1386650760

Payments from drug & device makers

$25,181in general payments, 2019–2025

Across 1,467 payments — averaging $17.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$7K
  • AbbVie$4K
  • UCB, Inc.$2K
  • Johnson & Johnson$2K
  • Pfizer$2K
  • AstraZeneca$2K
  • plus $7K from 20 others

What the payments were for

  • Food & beverage$24,90999%
  • Education$2721%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$25,181 in reported general payments places this provider in the 85th percentile of 26 rheumatology providers in West Virginia.

See all rheumatology providers in West Virginia

Medicare billing

Part B allowed, 2024
$143,479
Medicare patients
353
Services billed
6,407

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Enbrel SureclickEtanercept65$542,237
Humira(Cf) PenAdalimumab34$281,713
PanzygaImmun Glob G(Igg)-Ifas/Glycine15$198,260
Cosentyx Sensoready (2 Pens)Secukinumab15$177,231
OtezlaApremilast20$134,338
Xeljanz XrTofacitinib Citrate11$128,088
Cosentyx Sensoready PenSecukinumab11$98,325
Taltz AutoinjectorIxekizumab14$96,098
OrenciaAbatacept13$69,205
Cimzia (2 Pack)Certolizumab Pegol12$67,532
RidauraAuranofin17$41,929
Hydroxychloroquine Sulfate734$26,291
MethotrexateMethotrexate Sodium564$8,912
Leflunomide134$5,234
Prednisone797$4,046

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerPanzyga$1,919$198,26015 claims
AmgenOtezla$6,509$134,33820 claims
E.r. Squibb & Sons, L.L.C.Orencia$489$69,20513 claims
UCB, Inc.Cimzia (2 Pack)$2,240$67,53212 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 26 rheumatology providers in West Virginia.

Other rheumatology in South Charleston

See the full list for West Virginia

Where these figures come from

Is this you, or does something look wrong? →